“The AAN (American Academy of Neurology) supports all efforts to allow for rigorous research to evaluate the long-term safety and efficacy of medical marijuana and compounds derived from the plant. This includes proposals that increase access for the study of medical marijuana under IRB-approved research protocols and the reclassification of medical marijuana from its current Schedule I status to Schedule II to allow for medical research.”